http://www.fh-partners.com/home daily 1.0 2016-05-17 https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57154683356fb0cbba8601db/1461012104776/ Home https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5712fabc60b5e92c3a254b6f/1460861633797/ Home https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57154896746fb986183794fc/1461012635160/ Home https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5712fad0c2ea51df8fbecb07/1460861652156/ Home https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5733f62dc6fc0897c471e270/1463023151821/iStock_000077086305_reduced_cropped.jpg Home https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5733f65fc6fc0897c471e3bf/1463023202211/iStock_000057699204_reduced.jpg Home https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5733f6b4c6fc0897c471e581/1463023286445/iStock_000083112477_reduced.jpg Home https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5733f68fc6fc0897c471e4c6/1463023250548/iStock_000000463729_reduced.jpg Home http://www.fh-partners.com/news-entries daily 0.75 2017-10-16 https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5712cfb6e707eb7f22b1f737/1460850616118/stock-photo-1619803-foxglove-digitalis-purpurea-flowers_cropped.jpg News Entries http://www.fh-partners.com/news-entries/2016/1/8/vivasure-medical-receives-ce-mark-for-first-and-only-fully-bioabsorbable-percutaneous-closure-device-for-large-bore-transcatheter-procedures monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2016/4/21/innocoll-holdings-plc-appoints-lesley-russell-mbchb-mrcp-as-chief-medical-officer monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2016/4/21/amarin-reaches-target-enrollment-in-cardiovascular-outcomes-study-of-vascepar-in-patients-with-elevated-triglycerides-despite-statin-therapy monthly 0.5 2016-04-24 http://www.fh-partners.com/news-entries/2016/3/17/innocoll-holdings-plc-announces-fourth-quarter-and-full-year-2015-financial-and-operating-results-and-provides-corporate-update monthly 0.5 2016-04-21 http://www.fh-partners.com/news-entries/2016/4/26/chrono-therapeutics-smoking-cessation-technology-demonstrates-significant-reduction-in-nicotine-cravings monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2016/3/7/spark-therapeutics-announces-acquisition-of-genable-technologies monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2016/2/10/mainstay-medical-full-year-2015-preliminary-results-and-business-update monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/12/17/innocoll-ag-appoints-charles-katzer-as-head-of-manufacturing-and-technical-operations monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/12/16/neuravi-announces-meeting-of-world-stroke-leaders-at-inaugural-clot-summit-2015 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/12/10/innocoll-ag-announces-plan-to-move-corporate-domicile-to-ireland monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/12/4/additional-data-confirm-positive-results-for-clinical-trial-of-reactiv8 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/11/5/neuravi-announces-first-patient-treated-in-international-pivotal-clinical-trial-of-novel-stent-retriever-for-acute-ischemic-stroke monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/11/2/mainstay-medical-applies-for-ce-mark-for-reactiv8 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/10/1/neuravi-announces-european-launch-of-innovative-minimally-invasive-stroke-therapy monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/9/30/neuromod-announces-55-million-in-financing-to-advance-neuromodulation-based-medical-device-to-treat-chronic-tinnitus monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/9/16/innocoll-ag-announces-first-patient-dosed-in-the-xaracoll-matrix-2-phase-3-study-for-the-treatment-of-postoperative-pain monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/9/1/neuravi-ltd-appoints-experienced-neurovascular-executive-robert-stern-to-board-of-directors monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/9/14/innocoll-ag-announces-departure-of-chief-medical-officer monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/9/2/innocoll-ag-announces-first-patient-dosed-in-the-xaracoll-matrix-1-phase-3-study-for-the-treatment-of-postoperative-pain monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/8/31/mainstay-medical-announces-half-year-financial-results monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/8/31/positive-results-for-mainstay-medicals-clinical-trial-of-reactiv8 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/8/26/chrono-therapeutics-receives-second-fast-track-sbir-grant-from-national-cancer-institute-for-patient-individualized-smoking-cessation-therapy monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/8/24/mainstay-medical-secures-15m-debt-financing monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/8/8/first-amendment-decision-a-win-for-amarin-and-physician-plaintiffs monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/8/13/innocoll-ag-appoints-rich-fante-as-chief-commercial-officer-and-head-of-business-development monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/7/15/mainstay-medical-announces-two-additional-us-patents-issued monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/7/1/innocoll-ag-appoints-jose-carmona-as-chief-financial-officer monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/6/30/innocoll-ag-announces-qualified-infectious-disease-product-qidp-designation-for-cogenzia-for-the-adjunctive-treatment-of-moderate-and-severe-diabetic-foot-infection monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/6/22/mainstay-medical-strengthens-board-with-new-independent-director monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/6/17/neuravi-announces-19m-21m-in-financing-to-advance-innovative-minimally-invasive-stroke-therapy monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/6/16/innocoll-ag-announces-first-patient-dosed-in-the-cogenzia-coact-2-phase-3-study-for-the-treatment-of-diabetic-foot-infection monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/5/29/mainstay-medical-gains-approval-to-start-us-clinical-trial-of-reactiv8 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/5/15/innocoll-ag-announces-first-patient-dosed-in-the-cogenzia-coact-1-phase-3-study-for-the-treatment-of-diabetic-foot-infection monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/5/12/mainstay-medical-interim-management-statement monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/4/24/innocoll-ag-announces-pricing-of-follow-on-offering monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/4/1/pivotal-pharmacokinetic-study-of-innocolls-xaracoll-supports-use-of-300-mg-dose-for-phase-3-clinical-studies-in-post-operative-pain monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/3/30/innocoll-ag-secures-eur-25-million-loan-commitment-from-european-investment-bank-eib monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/3/19/mainstay-medical-announces-2014-financial-results monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/3/19/innocoll-ag-announces-fourth-quarter-and-full-year-2014-financial-and-operating-results monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/3/18/innocoll-ag-appoints-james-tursi-md-as-chief-medical-officer monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/3/3/chrono-therapeutics-receives-investment-from-rock-health-to-advance-smartstoptm-smoking-cessation-technology monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/3/2/opsona-therapeutics-ltd-commences-part-b-of-phase-ii-study-of-blocking-toll-like-receptor-2-in-extended-criteria-donor-renal-transplant-recipients-at-high-risk-of-early-graft-dysfunction monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/2/23/opsona-therapeutics-ltd-patent-issued-in-usa-covering-an-antibody-directed-against-toll-like-receptor-2-tlr-2-and-the-use-and-development-thereof monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/1/26/mainstay-medical-applies-to-start-us-clinical-trial-of-reactiv8 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2015/1/26/opsona-therapeutics-ltd-initiates-phase-iii-study-in-a-first-in-class-monoclonal-antibody-that-blocks-toll-like-receptor-2 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/12/5/mainstay-medical-achieves-quality-system-certification monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/12/8/innocoll-ag-appoints-tony-zook-as-chief-executive-officer-as-company-progresses-toward-becoming-a-fully-integrated-commercial-company monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/12/5/sagentia-selected-as-lead-development-partner-for-chrono-therapeutics-wearable-smart-smoking-cessation-device monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/11/13/innocoll-ag-announces-third-quarter-2014-financial-and-operating-results monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/11/6/mainstay-medical-interim-management-statement monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/10/22/acorda-therapeutics-completes-acquisition-of-civitas-therapeutics monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/9/10/genable-technologies-ltd-moving-gt038-into-full-development monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/9/2/neuravi-introduces-collaborative-clot-research-initiative-at-esmint-conference-in-september monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/8/27/civitas-therapeutics-files-registration-statement-for-proposed-initial-public-offering monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/7/30/innocoll-ag-announces-closing-of-initial-public-offering monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/8/25/civitas-therapeutics-secures-55-million-in-series-c-financing monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/6/12/chrono-therapeutics-inventor-of-wearable-smart-smoking-cessation-technology-secures-32-million-in-series-a-financing monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/7/7/mainstay-medical-announces-pre-ide-submission-for-reactiv8-to-fda monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/6/30/mainstay-medical-announces-expansion-of-clinical-trial-of-reactiv8-for-people-with-chronic-low-back-pain-to-belgium monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/5/29/mainstay-announces-the-partial-exercise-of-the-over-allotment-option-increasing-the-gross-proceeds-of-the-offer-to-approximately-188m monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/3/25/spark-therapeutics-and-genable-technologies-announce-collaboration-to-advance-a-gene-therapy-treatment-for-a-rare-form-of-retinitis-pigmentosa monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/11/22/leading-international-blindness-charities-welcome-genables-enhanced-patent-portfolio monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/4/9/mainstay-medical-announces-intention-to-launch-initial-public-offering-and-list-on-euronext-paris-and-on-the-enterprise-securities-market-of-irish-stock-exchange monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/4/28/mainstay-medical-international-plc-announcement-of-offer-price-and-number-of-issued-ordinary-shares-on-admission-to-euronext-paris-and-esm monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/3/10/mainstay-medical-begins-clinical-trial-of-reactiv8-for-people-with-chronic-low-back-pain monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/2/2/mainstay-medical-strengthens-board monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/5/7/palyon-medical-and-core-manufacturing-announce-strategic-partnership monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/4/28/civitas-therapeutics-announces-positive-phase-2b-results-for-cvt-301-inhaled-levodopa-for-the-treatment-of-parkinsons-disease monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/1/29/civitas-therapeutics-appoints-mark-iwicki-president-and-chief-executive-officer monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2014/1/8/civitas-therapeutics-appoints-timothy-s-nelson-as-chairman-of-the-board-of-directors monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/11/12/civitas-therapeutics-extends-cvt-301-patent-protection-into-2032 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/10/2/opsona-therapeutics-limited-raises-an-additional-3-million-usd-4-million-from-omnes-capital-in-series-c-extension-resulting-in-a-total-financing-round-of-36-million-usd-486-million monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/9/11/civitas-therapeutics-secures-38-million-in-financing monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/9/5/civitas-therapeutics-initiates-phase-2b-clinical-study-of-cvt-301-inhaled-l-dopa-for-parkinsons-disease monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/6/18/civitas-therapeutics-receives-second-grant-for-their-lead-product-cvt-301-from-the-michael-j-fox-foundation-for-parkinsons-research monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/6/19/amarin-informed-by-fda-of-october-16th-advisory-committee-date-in-connection-with-supplemental-new-drug-application-snda-for-vascepar monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/5/28/trino-therapeutics-secures-series-a-investment-of-over-9m-12m-for-a-novel-oral-drug-therapy-for-mild-to-moderate-ulcerative-colitis monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/5/13/genable-technologies-ltd-appoints-annette-clancy-as-chairman-of-the-board monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/5/7/opsona-therapeutics-ltd-initiates-a-phase-ii-study-with-opn-305 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/4/29/opsona-therapeutics-limited-raises-33-million-us43-million-oversubscribed-series-c-equity-financing-to-advance-clinical-development-of-its-lead-product-opn-305 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/4/19/civitas-therapeutics-announces-positive-phase-2-clinical-results-for-cvt-301-an-inhaled-l-dopa-for-parkinsons-disease monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/4/12/designation-by-fda-for-gene-therapy-product-gt308 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2013/2/1/mainstay-medical-appoints-oern-r-stuge-md-as-chairman-of-the-board monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2012/10/16/civitas-therapeutics-to-present-positive-clinical-study-results-for-cvt-301-at-sixth-annual-parkinsons-disease-therapeutics-conference monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2012/9/26/mainstay-medical-completes-200m-153m-oversubscribed-series-b-venture-financing monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2012/9/5/civitas-therapeutics-appoints-bryan-e-stuart-chief-business-officer monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2012/7/11/irish-medical-device-company-neuravi-completes-52m-series-a-financing monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2011/11/29/civitas-therapeutics-announces-award-of-michael-j-fox-foundation-grant-and-lead-drug-candidate-for-parkinsons-disease monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2012/4/17/opsona-therapeutics-announces-the-issuance-of-new-patent-from-the-european-patent-office-epo-covering-the-development-and-use-of-an-antibody-directed-against-toll-like-receptor-tlr-2 monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2012/6/15/civitas-therapeutics-initiates-phase-2a-clinical-study-of-cvt-301-an-inhaled-l-dopa-for-parkinsons-disease monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2011/11/11/irelands-genable-technologies-completes-5m-series-b-financing monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2011/9/26/amarin-announces-nda-submission-for-amr101-for-the-treatment-of-patients-with-very-high-triglycerides monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2011/7/12/civitas-therapeutics-secures-5m-in-financing-accelerating-parkinsons-disease-program monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2011/7/5/opsona-therapeutics-announces-initiation-of-a-phase-1-clinical-trial-with-its-lead-drug monthly 0.5 2016-04-26 http://www.fh-partners.com/news-entries/2011/8/10/amarin-announces-agreement-from-fda-on-special-protocol-assessment-for-amr101-outcomes-study monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2011/5/31/amarin-announces-global-supply-network-for-amr101 monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2011/5/19/amarin-sponsored-posters-to-be-presented-today-at-the-national-lipid-association-2011-annual-scientific-sessions monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2011/5/19/additional-detail-of-successful-marine-phase-iii-trial-to-be-presented-at-the-national-lipid-association-2011-annual-scientific-sessions monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2011/5/6/opsona-therapeutics-appoints-chairman-dr-bernd-r-seizinger-as-executive-chairman-dr-mark-heffernan-resigns-as-ceo-but-remains-as-non-executive-director monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2011/5/6/european-commission-awards-eur-59m-to-opsona-therapeutics-for-clinical-development-of-lead-drug-candidate-opn-305 monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2011/5/6/dr-leon-hooftman-appointed-chief-medical-officer-as-opsona-therapeutics-transitions-into-the-clinic monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2011/4/18/amarins-amr101-phase-3-anchor-trial-meets-all-primary-and-secondary-endpoints monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2011/1/6/amarin-corporation-announces-the-pricing-of-an-underwritten-public-offering monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/12/20/cappella-medical-systems-announces-first-placements-of-its-new-dual-marker-sideguard-system monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/12/15/amarin-completes-patient-randomization-in-phase-3-anchor-trial monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/12/7/cappella-medical-systems-wins-top-medical-technology-industry-awards monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/11/29/amarins-amr101-meets-pivotal-phase-3-study-endpoints monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/11/10/amarin-reports-third-quarter-2010-financial-results-and-positively-updates-phase-3-guidance monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/11/10/amarin-corporation-announces-senior-management-changes monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/11/18/amarin-corporation-appoints-kristine-peterson-to-board-of-directors monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/11/1/cappella-inc-completed-the-first-tranche-of-a-105-million-series-d-investment monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/8/24/luis-malave-joins-palyon-corporation-as-ceo monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/8/18/insulet-announces-departure-of-chief-operating-officer monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/8/17/amarin-corporation-appoints-colin-w-stewart-as-president-and-chief-executive-officer monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/8/10/amarins-amr101-pivotal-phase-3-marine-clinical-trial-completes-patient-enrollment-and-randomization-trial-guidance-positively-updated monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/8/10/amarin-reports-q2-2010-results-marine-trial-results-due-early-2011-anchor-trial-50-randomized-conference-call-today monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/6/22/eamonn-hobbs-accepts-appointment-as-chairman-of-the-board-of-directors-of-cappella monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/6/14/david-blossom-joins-cappella-as-vice-president-commercial-operations monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2010/5/13/amarin-reports-q1-2010-results monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2009/12/2/amarin-corporation-appoints-industry-veteran-joseph-zakrzewski-as-executive-chairman monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2009/11/16/cappella-inc-announces-initiation-of-sideguard-3 monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2009/11/6/amarin-appoints-john-f-thero-as-chief-financial-officer monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2009/10/19/amarin-announces-completion-of-70-million-private-placement monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2009/10/13/amarin-announces-changes-to-its-board-and-management-team monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2009/6/15/cappella-inc-secures-173-million-series-c-investment monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2009/4/29/palyon-medical-corporation-secures-21-million-series-a-investment monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2009/5/19/nextech-venture-participates-in-the-24m-financing-of-palyon-medical monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2009/2/18/opsona-therapheutics-closes-18m-funding monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2008/5/14/amarin-announces-private-placement-for-up-to-60-million monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2008/7/22/amarin-proceeding-to-phase-3-with-amr101-for-hypertriglyceridemia monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2012/9/7/new-chairman-for-irish-venture-capital-association monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2015/1/9/fountain-healthcare-partners-launches-second-fund monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2008/4/29/launch-of-fountain-healthcare-partners-a-life-science-venture-capital-firm monthly 0.5 2016-04-27 http://www.fh-partners.com/news-entries/2016/5/3/neuravi-strengthens-patent-portfolio-for-novel-stent-retrievers-with-newly-issued-us-and-european-patents monthly 0.5 2016-05-03 http://www.fh-partners.com/news-entries/2016/5/25/innocoll-announces-xaracoll-bupivacaine-collagen-bioresorbable-implant-meets-primary-endpoint-in-both-pivotal-phase-3-trials-in-postoperative-pain-relief monthly 0.5 2016-05-25 http://www.fh-partners.com/news-entries/2016/5/25/mainstay-medical-achieves-ce-markingfor-reactiv8and-prepares-for-commercial-launch-in-germany monthly 0.5 2016-05-25 http://www.fh-partners.com/news-entries/2016/5/31/amarin-announces-fda-new-chemical-entity-market-exclusivity-determination-for-vascepar-icosapent-ethyl-capsules monthly 0.5 2016-05-31 http://www.fh-partners.com/news-entries/2016/6/11/vascepar-icosapent-ethyl-showed-significant-reductions-in-potentially-atherogenic-lipid-parameters-in-statin-treated-patients-with-type-2-diabetes-and-persistent-high-triglycerides monthly 0.5 2016-06-17 http://www.fh-partners.com/news-entries/2016/6/17/mainstay-medical-announces-30-million-fundraising monthly 0.5 2016-06-17 http://www.fh-partners.com/news-entries/2016/6/17/innocoll-holdings-plc-announces-pricing-of-public-offering-of-ordinary-shares monthly 0.5 2016-06-17 http://www.fh-partners.com/news-entries/2016/6/23/innocoll-holdings-plc-announces-the-completion-of-enrollment-in-two-pivotal-phase-3-clinical-trials-of-cogenzia-for-the-treatment-of-diabetic-foot-infections monthly 0.5 2016-06-23 http://www.fh-partners.com/news-entries/2016/7/25/neuravi-selects-robert-colloton-to-lead-us-commercialization-of-innovative-stent-retriever monthly 0.5 2016-08-09 http://www.fh-partners.com/news-entries/2016/8/17/innocoll-holdings-plc-announces-second-quarter-2016-financial-and-operating-results-and-provides-corporate-update monthly 0.5 2016-08-17 http://www.fh-partners.com/news-entries/2016/9/8/vivasure-medical-announces-162m-183m-in-financing-to-advance-commercialization-of-closure-device-in-european-union-and-united-states monthly 0.5 2016-09-08 http://www.fh-partners.com/news-entries/2016/9/8/chrono-therapeutics-raises-476-million-in-series-b-financing-to-advance-its-clinical-platform-for-personalized-drug-therapy monthly 0.5 2016-09-08 http://www.fh-partners.com/news-entries/2016/9/8/neuravi-announces-european-launch-of-embotrap-ii-stent-retriever-for-the-treatment-of-acute-stroke monthly 0.5 2016-09-08 http://www.fh-partners.com/news-entries/2016/9/12/inflazome-closes-a-17m-series-a-round-from-novartis-venture-fund-and-fountain-healthcare-partners-to-develop-treatments-for-chronic-inflammatory-diseases monthly 0.5 2016-09-12 http://www.fh-partners.com/news-entries/2016/9/14/mainstay-medicals-reactiv8-b-clinical-trial-for-treatment-of-chronic-low-back-pain-enrolls-first-subject monthly 0.5 2016-09-14 http://www.fh-partners.com/news-entries/2016/9/20/mainstay-medical-international-plc-reactiv8-a-clinical-trial-sustained-performance-at-one-year monthly 0.5 2016-09-20 http://www.fh-partners.com/news-entries/2016/9/23/mainstay-medical-announces-half-year-financial-results monthly 0.5 2016-09-23 http://www.fh-partners.com/news-entries/2016/10/6/first-subject-implanted-in-mainstay-medicals-reactiv8-b-clinical-trial-for-treatment-of-chronic-low-back-pain monthly 0.5 2016-10-06 http://www.fh-partners.com/news-entries/2016/10/25/opsona-therapeutics-ltd-receives-orphan-designation-for-myelodysplastic-syndrome-mds-with-opn-305-a-first-in-class-monoclonal-antibody-that-blocks-toll-like-receptor-2 monthly 0.5 2016-10-25 http://www.fh-partners.com/news-entries/2016/10/26/mainstay-medical-announces-additional-us-patent-issued monthly 0.5 2016-10-26 http://www.fh-partners.com/news-entries/2016/10/27/vivasure-medical-appoints-robert-chip-hance-to-companys-board-of-directors monthly 0.5 2016-10-27 http://www.fh-partners.com/news-entries/2016/11/2/neuravi-secures-15-million-to-fund-expansion monthly 0.5 2016-11-02 http://www.fh-partners.com/news-entries/2016/11/3/innocoll-announces-top-line-data-from-phase-3-trials-with-cogenzia-and-nda-submission-for-xaracoll monthly 0.5 2016-11-03 http://www.fh-partners.com/news-entries/2016/11/22/opsona-therapeutics-ltd-to-present-preliminary-results-from-ongoing-study-in-second-line-lower-risk-myelodysplastic-syndrome-at-the-58th-annual-meeting-of-the-american-society-of-hematology-ash monthly 0.5 2016-11-22 http://www.fh-partners.com/news-entries/2016/11/22/innocoll-holdings-plc-announces-third-quarter-2016-financial-and-operating-results-and-provides-corporate-update monthly 0.5 2016-12-09 http://www.fh-partners.com/news-entries/2016/12/20/opsona-therapeutics-ltd-announces-preliminary-results-from-ongoing-study-in-second-line-lower-risk-mds-recently-presented-at-the-58th-annual-ash-meeting monthly 0.5 2016-12-22 http://www.fh-partners.com/news-entries/2016/12/30/innocoll-receives-refusal-to-file-letter-from-us-fda-for-xaracoll-bupivacaine-hcl-collagen-matrix-implants-new-drug-application monthly 0.5 2016-12-30 http://www.fh-partners.com/news-entries/2017/1/5/nerre-therapeutics-raises-23million-in-oversubscribed-series-b-financing-round monthly 0.5 2017-01-13 http://www.fh-partners.com/news-entries/2017/1/12/mainstay-medical-applies-for-approval-to-market-reactiv8-in-australia monthly 0.5 2017-01-13 http://www.fh-partners.com/news-entries/2017/2/1/mainstay-medical-starts-commercialization-of-reactiv8-for-the-treatment-of-chronic-low-back-pain monthly 0.5 2017-02-01 http://www.fh-partners.com/news-entries/2017/2/21/neuravi-announces-completion-of-patient-enrollment-in-clinical-trial-of-a-novel-stent-retriever-for-acute-ischemic-stroke monthly 0.5 2017-04-10 http://www.fh-partners.com/news-entries/2017/3/16/innocoll-holdings-plc-announces-fourth-quarter-and-full-year-2016-financial-and-operating-results-and-provides-corporate-update monthly 0.5 2017-03-16 http://www.fh-partners.com/news-entries/2017/3/16/innocoll-holdings-announces-statement-re-possible-offer monthly 0.5 2017-03-16 http://www.fh-partners.com/news-entries/2017/3/23/mainstay-medical-publishes-2016-full-year-results-and-business-update monthly 0.5 2017-03-23 http://www.fh-partners.com/news-entries/2017/3/29/innocoll-announces-regulatory-path-forward-after-receiving-formal-fda-type-a-meeting-minutes-regarding-its-xaracoll-bupivacaine-hcl-collagen-matrix-implant-new-drug-application monthly 0.5 2017-03-29 http://www.fh-partners.com/news-entries/2017/4/5/gurnet-point-lp-enters-into-agreement-to-acquire-innocoll-holdings-plc monthly 0.5 2017-04-05 http://www.fh-partners.com/news-entries/2017/4/10/codman-neuro-announces-acquisition-of-neuravi-limited-to-accelerate-innovation-in-acute-ischemic-stroke-therapy monthly 0.5 2017-04-10 http://www.fh-partners.com/news-entries/2017/5/9/mainstay-medical-starts-commercialization-of-reactiv8-for-the-treatment-of-chronic-low-back-pain-in-ireland monthly 0.5 2017-05-09 http://www.fh-partners.com/news-entries/2017/8/3/mainstay-medicals-reactiv8-b-clinical-trial-passes-mid-point monthly 0.5 2017-08-03 http://www.fh-partners.com/news-entries/2017/9/5/mainstay-medical-announces-ceo-leadership-transition monthly 0.5 2017-09-05 http://www.fh-partners.com/news-entries/2017/9/5/mainstay-medical-announces-half-year-financial-results monthly 0.5 2017-09-05 http://www.fh-partners.com/news-entries/2017/9/27/kandy-therapeutics-launched-to-advance-a-breakthrough-treatment-in-womens-health monthly 0.5 2017-09-27 http://www.fh-partners.com/news-entries/2017/9/27/nerre-therapeutics-appoints-andrew-kay-as-chairman-of-the-board monthly 0.5 2017-09-27 http://www.fh-partners.com/news-entries/2017/10/9/mainstay-medical-jason-hannon-joins-board-of-directors-begins-his-role-as-ceo monthly 0.5 2017-10-09 http://www.fh-partners.com/news-entries/2017/10/16/vivasure-enrolls-first-patient-in-frontier-iv-clinical-trial monthly 0.5 2017-10-16 http://www.fh-partners.com/home-headshots daily 0.75 2016-05-12 https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/570b1bf720c64757953e868a/1460347062533/HP1.png Patient Headshots Health is precious.   https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/57130095c2ea51df8fbee335/1460863150911/Susan.png Patient Headshots https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/5717e8f3f85082df1d4de1f1/1461185782268/Frank_2.png Patient Headshots https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/5717eaee859fd0a511ea2b92/1461185321762/Martha_2.png Patient Headshots https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/5717ed67b09f95cb2ea2e15b/1461614573254/Frank_2.png Patient Headshots Frank needs to quit smoking. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/571ede414d088ebb7161079c/1463023416697/iStock_000054340724_reduced.jpg Patient Headshots Frank needs to quit smoking. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/571ede40d210b8548ed7d2fb/1463023439387/iStock_000028090504_reduced.jpg Patient Headshots Jeff needs his back pain to go away. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/571ede91d210b8548ed7d543/1463023484387/iStock_000078497143_reduced.jpg Patient Headshots Susan needs to stop the ringing in her ears. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/571ede7c4d088ebb71610974/1463023460235/iStock_000057074882_reduced.jpg Patient Headshots Martha needs to recover from her stroke. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5733f77cf8baf3a11078e4e0/1461614573254/ Patient Headshots Frank needs to quit smoking. http://www.fh-partners.com/portfolio daily 0.75 2017-09-27 https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/571810172eeb81a76002aaa1/1463501198059/ Portfolio   Genable developed a gene therapy platform to suppress and replace genes associated with Retinitis Pigmentosa. The company was acquired by Spark Therapeutics in March 2016. Fountain has exited this investment. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/576412efd2b8578a71f18da3/1466176245378/ Portfolio   Using a proprietary collagen-based technology, Innocoll is developing a portfolio of products to treat post-operative pain and prevent post-surgical adhesions. Innocoll was listed on NASDAQ as INNL prior to its acquisition by Gurnet Point in 2017 https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/571811a5c2ea51643d917557/1483620910739/ Portfolio   Using neuromodulation treatments, Neuromod is helping people with chronic and often debilitating tinnitus, informally called "ringing in the ears." https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57180ac462cd9432474dd056/1461205844420/ Portfolio   Leveraging oral small molecules, Trino Therapeutics was focused on treating and managing inflammatory indications such as inflammatory bowel disease (IBD). The company ceased operations in 2017 and this investment is inactive. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57d70f9337c581ee83eb253d/1473712297590/ Portfolio   Inflammasomes generate signals that cause immune cells to fight infections. Inflazome is developing novel treatments for inflammation-related diseases by precisely blocking unwanted inflammasome signals. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57180aa6356fb0279225b220/1463501117696/ Portfolio   Targeting the human immune system, Opsona is developing drugs with wide applicability to conditions such as autoimmune and inflammatory diseases, solid organ transplantation and oncology. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/571808e4859fd0a511eb3498/1461205749527/ Portfolio   With extensive experience in lipid science, Amarin is developing novel therapeutics for the treatment of cardiovascular disorders. Fountain has exited this investment. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57183bf7b654f9456e06f687/1461206123090/ Portfolio   Cappella built and distributed a bifurcation stent to protect coronary sidebranch arteries during cardiac procedures. Now called ArraVasc Limited, they are focused on peripheral vascular products. This investment is inactive. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5718128586db436a37926221/1461195402434/ Portfolio https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5728d56259827e6e7a176de9/1462293865068/ Portfolio   With a portfolio of unique interventional neurovascular devices, Neuravi is improving clinical outcomes for stroke patients. Johnson & Johnson acquired the company in March 2017. Fountain has exited this investment. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/570b1bf720c64757953e868a/1460347062533/HP1.png Portfolio Health is precious.   https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/57130095c2ea51df8fbee335/1460863150911/Susan.png Portfolio https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/5717e8f3f85082df1d4de1f1/1461185782268/Frank_2.png Portfolio https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/5717eaee859fd0a511ea2b92/1461185321762/Martha_2.png Portfolio https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/5717ed67b09f95cb2ea2e15b/1461614573254/Frank_2.png Portfolio Frank needs to quit smoking. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/571ede414d088ebb7161079c/1463023416697/iStock_000054340724_reduced.jpg Portfolio Frank needs to quit smoking. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/571ede40d210b8548ed7d2fb/1463023439387/iStock_000028090504_reduced.jpg Portfolio Jeff needs his back pain to go away. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/571ede91d210b8548ed7d543/1463023484387/iStock_000078497143_reduced.jpg Portfolio Susan needs to stop the ringing in her ears. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/570b19c22b8dde64de16f632/571ede7c4d088ebb71610974/1463023460235/iStock_000057074882_reduced.jpg Portfolio Martha needs to recover from her stroke. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/58f994319f7456dd4586d285/1506518762821/ Portfolio Velicept is developing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57180aeb356fb0279225b433/1461205887906/ Portfolio   Following a successful IPO, Mainstay Medical (MSTY) is bringing to market an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP). https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/59cac9a18fd4d227d5af4dc6/1506518798108/ Portfolio KaNDy Therapeutics is a UK based clinical-stage company focused on developing NT-814, a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS). https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5718129627d4bde89977ead3/1461195418941/ Portfolio https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/586e42e6e6f2e1de112e4344/1506518704013/NerreThera.png Portfolio Developing a unique portfolio of neurokinin (NK) receptor antagonists, NeRRe Therapeutics is aiming to treat common debilitating respiratory and women's health conditions caused by neuronal hypersensitivity. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57180eaf55598636257837b7/1461206073264/ Portfolio   With an implantable infusion pump, Palyon Medical was treating chronic pain, spasticity and diseases of the central nervous system. The company ceased operations in 2015 and this investment is inactive. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57d7115d579fb30c254d0c26/1473712481633/ Portfolio   Chrono is combining a biologically timed transdermal drug delivery system with a behavorial support delivered via an app to help people manage hard-to-treat conditions. Their first application is smoking cessation. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57180bc2859fd0a511eb4a3d/1461205941353/ Portfolio   Aiming to help people undergoing vascular surgery, Vivasure Medical has developed a bioabsorbable technology delivered percutaneously to assist in vessel closure. https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57180912a3360ca6b6d5bb32/1461205795291/ Portfolio   Before being acquired by Acorda Therapeutics for $525M in cash in October 2014, Civitas was applying its dry powder inhalation drug delivery technology to Parkinson’s treatments. Fountain has exited this investment. http://www.fh-partners.com/team daily 0.75 2017-09-26 https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57bbc025e3df2846532470f8/1471922240034/ Team https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57bbc06a6a4963629636673f/1471922310879/ Team https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57bbc11fb3db2bd0d1160625/1471922471320/ Team https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/57bbc08fe3df2846532474b2/1471922350545/ Team https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5733f6db3c44d8160cfa169e/1463023325217/iStock_000000881721_reduced.jpg Team http://www.fh-partners.com/submit-plan daily 0.75 2016-04-25 https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/571e46d760b5e939435297fe/1461602010442/stock-photo-57196602-light-bulbs.jpg Submit Plan http://www.fh-partners.com/news daily 0.75 2016-04-27 https://static1.squarespace.com/static/56fd4fc09f726631f41fd683/t/5733f709c6fc0897c471e75c/1463023371882/iStock_000010682054_reduced.jpg News